Determinants of plasma levels of plasminogen activator inhibitor-1: A study of normotensive twins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 2, 1999, Pages 316-320

  Cesari, Maurizio ^b   Sartori, Maria Teresa ^b   Patrassi, Giovanni M ^b   Vettore, Silvia ^b   Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NONE

Author keywords

Fibrinolysis; Gene polymorphism; Humans; Plasminogen activator inhibitor type 1; Twins

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; DNA DETERMINATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; TWIN ZYGOSITY;

EID: 0032967384     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.2.316     Document Type: Article

References (27)

1. Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost. 1991;66:321-328.
2. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-76.
3. Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J. 1986;55:58-66.
4. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
5. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
6. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57:67-72.
7. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis. 1991;34:179-192.
8. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol. 1990;47:1075-1079.
9. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries, SE, Evans A, Luc G, Cambou JP, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost. 1995;74:837-841.
10. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol. 1997;17:851-858.
11. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997; 17:33-37.
12. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
13. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating leels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
14. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183-190.
15. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37-42.
16. Ansley D. Aging twins offer clues to late-onset disease. Science. 1993; 259:1826-1828.
17. Rossi GP, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin GP, Ganten D, Pessina AC. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci. 1997;93:435-443.
18. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
19. Falk G, Almquist A, Nordenhem A, Svensson H, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis. 1995;9:170-174.
20. Rosner B. Fundamentals of Biostatics. 2nd ed. Boston, Mass: PWS Publisher; 1996.
21. Williams CJ, Christian JC, Norton JAJ. TWINAN90: a FORTRAN program for conducting ANOVA-based and likelihood-based analyses of twin data. Comput Methods Programs Biomed. 1992;38:167-176.
22. Christian JC, Norton JAJ, Sorbel J, Williams CJ. Comparison of analysis of variance and maximum likelihood based path analysis of twin data: partitioning genetic and environmental sources of covariance. Genet Epidemiol. 1995;12:27-35.
23. Hong Y, Pedersen NL, Egberg N, de Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vasc Biol. 1997;17:2776-2782.
24. Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visviskis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. Arterioscler Thromb Vasc Biol. 1998;18: 84-91.
25. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost. 1995;74:1032-1034.
26. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
27. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S, Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol. 1997;17:755-759.